You can treat Fibroids without surgery. Hysterectomy and Myomectomy can be avoided by treating medically.
Medical treatment provides good symptom relief in some women, mainly in situations where bleeding is the dominant or only symptom. In general, 70 percent of women get some improvement over one year of therapy, but long-term failure rates are high.
Hormonal therapies — Combined hormonal contraceptives and progestational agents can be useful in some women with heavy menstrual bleeding, particularly those with coexisting problems (eg, dysmenorrhea or oligoovulation).
Estrogen-progestin contraceptives — Some women with heavy menstrual bleeding associated with leiomyomas respond to OC therapy. This, plus data that OCs are associated with a decreased risk of leiomyomas and reduced symptoms from other concurrent gynecologic conditions, suggests that a therapeutic trial may be appropriate before proceeding to more invasive therapies. The purported mechanism of action is via endometrial atrophy.
Levonorgestrel-releasing intrauterine system — Levonorgestrel-releasing intrauterine system (IUS) have shown a reduction in uterine volume and bleeding, and an increase in hematocrit after placement of this IUS . The device is widely used for control of heavy menstrual bleeding and is now approved by the United States Food and Drug Administration (FDA) for this indication. A second advantage of this treatment is that it provides contraception for women who do not desire pregnancy.
Progestin implants, injections, and pills — Progestin-only contraceptives cause endometrial atrophy and thus provide relief of menstrual bleeding-related symptoms. They can be considered for treatment of mild symptoms, especially for women who need contraception. There is also evidence from studies that these agents are associated with a decreased risk of leiomyoma formation.
Gonadotropin-releasing hormone agonists — Gonadotropin-releasing hormone (GnRH) agonists are the most effective medical therapy for uterine myomas. These drugs work by initially increasing the release of gonadotropins, followed by desensitization and downregulation to a hypogonadotropic, hypogonadal state that clinically resembles menopause. Most women will develop amenorrhea, improvement in anemia (if present), and a significant reduction (35 to 60 percent) in uterine size within three months of initiating this therapy.
Gonadotropin-releasing hormone antagonists — Similar clinical results have been achieved with GnRH antagonists, which compete with endogenous GnRH for pituitary binding sites . The advantage of antagonists over agonists is the rapid onset of clinical effects without the characteristic initial flare-up observed with GnRH agonist treatment.
Antifibrinolytic agents — Antifibrinolytic agents, which are useful in the treatment of idiopathic menorrhagia, have not been well studied in leiomyoma–related menorrhagia. One drug (tranexamic acid) is now available and FDA-approved for the treatment of heavy menstrual bleeding .
Danazol and gestrinone — Androgenic steroids may be an effective treatment of leiomyoma symptoms in some women, but are associated with frequent side effects.